Assay Development for SARS-CoV-2 Sero-Surveillance
- Funded by Government of Ontario (Canada)
- Total publications:0 publications
Grant number: unknown
Grant search
Key facts
Disease
COVID-19start year
-99Known Financial Commitments (USD)
$0Funder
Government of Ontario (Canada)Principal Investigator
Jennifer GommermanResearch Location
CanadaLead Research Institution
University of TorontoResearch Priority Alignment
N/A
Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Immunity
Special Interest Tags
N/A
Study Type
Unspecified
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
This study will provide a better understanding of the immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19. This approach aims to measure the level and/or types of antibodies induced by SARS-CoV-2 infection in the blood of acute and convalescent patients. In addition, measuring these antibodies in the saliva of asymptomatic infected subjects identified through contact tracing will provide insights into what the early immune response to the virus looks like, and how this may correlate with clinical outcome. This knowledge, as well as the development of a robust serosurveillance platform, represents a powerful weapon in our fight against COVID-19.